ArticlePloS one2025
Machine learning driven dashboard for chronic myeloid leukemia prediction using protein sequences.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of Leukaemia, a malignant blood cancer that originates from hematopoietic progenitor cells, is increasing in Southeast Asia, with a worrisome fatality rate of 54%. Predicting outcomes in the early stages is vital for improving the chances of patient recovery. The aim of this research is to enhance early-stage prediction systems in a substantial manner. Using Machine Learning and Data Science, we exploit protein sequential data from commonly altered genes including BCL2, HSP90, PARP, and RB to make predictions for Chronic Myeloid Leukaemia (CML). The methodology we implement is based on the utilisation of reliable methods for extracting features, namely Di-peptide Composition (DPC), Amino Acid Composition (AAC), and Pseudo amino acid composition (Pse-AAC). We also take into consideration the identification and handling of outliers, as well as the validation of feature selection using the Pearson Correlation Coefficient (PCA). Data augmentation guarantees a comprehensive dataset for analysis. By utilising several Machine Learning models such as Support Vector Machine (SVM), XGBoost, Random Forest (RF), K Nearest Neighbour (KNN), Decision Tree (DT), and Logistic Regression (LR), we have achieved accuracy rates ranging from 66% to 94%. These classifiers are thoroughly evaluated utilising performance criteria such as accuracy, sensitivity, specificity, F1-score, and the confusion matrix.The solution we suggest is a user-friendly online application dashboard that can be used for early detection of CML. This tool has significant implications for practitioners and may be used in healthcare institutions and hospitals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.